About
Technology
Issues
FAQ
Links
Official Page
Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.